“Our rise reflects years of commitment to building a truly comprehensive cancer center where scientific discovery and exceptional patient care advance hand in hand,” said Stephen D. Nimer, M.D., director of Sylvester. He said the center’s multidisciplinary teams are increasingly equipped to deliver experimental therapies and specialized treatments to patients with complex or difficult-to-treat cancers. This model links laboratory research with clinical practice, allowing discoveries in areas such as tumor biology, molecular diagnostics and therapeutic development to move more efficiently toward patient care.

Sylvester is the only National Cancer Institute-designated cancer center in South Florida, a designation that recognizes institutions with substantial research activity, advanced cancer programs and a commitment to reducing the burden of cancer. Its work spans basic science, population research, clinical investigation and direct treatment. This integrated structure is designed to improve the accuracy of diagnosis, identify biological differences between tumors and match patients with therapies that are more precisely suited to the molecular characteristics of their disease.

A central component of that effort is Sylvester’s academic Phase 1 Clinical Trials Program, described as the only program of its kind in South Florida. Phase 1 trials are generally the first studies in which a new drug, biologic therapy or treatment combination is tested in people. Researchers primarily evaluate safety, tolerability, dosage and how the treatment behaves in the body, although early signals of effectiveness may also emerge. For patients whose cancers have resisted standard therapies, these studies can provide access to treatments years before they become broadly available, while generating data needed for later-stage clinical development.

The center’s research capacity expanded substantially with the opening of the 12-story Kenneth C. Griffin Cancer Research Building in 2025. The facility doubled Sylvester’s research space and brought scientists, physicians, clinical investigators and data specialists into closer proximity. Such physical and organizational integration is important in translational medicine, which seeks to convert discoveries from laboratory models into diagnostic tools, clinical trials and treatments. Shared research environments can accelerate the analysis of tumor samples, the testing of candidate therapies and the development of data-driven approaches to predicting treatment response.

Sylvester is also extending cancer research and prevention beyond its main clinical facilities. Its Game Changer mobile program brings cancer screening, education and research opportunities to medically underserved communities across South Florida. Mobile outreach can help reduce barriers related to transportation, geography and access to specialty care, while screening programs may identify disease at earlier and more treatable stages. The center also leads a nationally recognized firefighter cancer initiative focused on research, prevention, screening and advocacy, addressing occupational exposures and other factors that may influence cancer risk in firefighting populations.

Additional programs target cancer survivorship and prevention. An NCI-funded effort is working to strengthen survivorship care through community health centers, where patients may receive long-term monitoring and support closer to home after completing treatment. Sylvester is also advancing lifestyle medicine and research on human papillomavirus-associated cancers. HPV can contribute to the development of several malignancies, including cervical, anal, oropharyngeal and other cancers. Combining vaccination, screening, behavioral interventions and molecular research may help reduce preventable disease and improve outcomes for people already diagnosed.

The latest rankings reflect performance across the wider UHealth system as well. Four additional programs earned national rankings, including ophthalmology, neurology and neurosurgery, geriatrics, and cardiology, heart and vascular surgery. Bascom Palmer Eye Institute retained the nation’s No. 1 position in ophthalmology for the 25th consecutive year. UHealth’s neurology and neurosurgery program ranked No. 14 nationally and includes more than 70 research and clinical faculty working across neurological subspecialties. Five other specialties—urology, diabetes and endocrinology, gastroenterology and gastrointestinal surgery, orthopedics, and pulmonology and lung surgery—received high-performing designations, placing them among the top 10% of hospitals nationwide.

Together, the results point to an expanding health system built around specialized care, research infrastructure and long-term patient management. “We are proud of what these results say about our progress, but our focus remains on what comes next,” said Dipen J. Parekh, M.D., chief executive officer of UHealth. He said the system would continue investing in people, innovation and specialized services. For Sylvester, the national rise is both a measure of recent progress and a sign of the competitive importance of connecting advanced cancer biology, early-phase clinical research, community prevention and comprehensive care within a single academic health system.

Subject of Research: Cancer research, clinical oncology, cancer prevention, Phase 1 clinical trials and translational medicine.

Article Title: Sylvester Cancer Center Rises to No. 23 Nationwide in 2026 U.S. News Rankings

News Publication Date: August 4, 2026

Web References: Sylvester Comprehensive Cancer Center: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center; Kenneth C. Griffin Cancer Research Building: https://umiamihealth.org/en/locations/sylvester-comprehensive-cancer-center-kenneth-c-griffin-cancer-research-building; UHealth rankings report: https://news.med.miami.edu/uhealth-highest-us-news-hospital-rankings-2026/

References: U.S. News & World Report 2026 Best Hospitals rankings; National Cancer Institute cancer center designation information; Sylvester Comprehensive Cancer Center announcement.

Image Credits: Sylvester Comprehensive Cancer Center

Keywords: Cancer, cancer research, clinical research, oncology, Phase 1 clinical trials, translational medicine, Sylvester Comprehensive Cancer Center, UHealth, University of Miami, National Cancer Institute, cancer prevention, survivorship care

CDK5RAP3, a cyclin-dependent kinase 5 regulatory subunit associated protein, has gained recognition as a potential tumor suppressor. Initially, research suggested that it plays a significant role in negatively regulating cell self-renewal and invasion processes in gastric cancer. This was primarily achieved through its regulatory interactions with the ERK1/2 signaling pathway, which is known to influence cell proliferation and survival under various physiological conditions. However, the integrity of the data supporting these claims has come under scrutiny.

The relevance of CDK5RAP3 in cancer biology cannot be understated, as its role could provide novel therapeutic targets. Its involvement raises pertinent questions about how signaling pathways can both promote and inhibit cancer progression. The original findings posited that CDK5RAP3 acts to curb the aggressive characteristics of cancer cells, specifically in regards to their invasive potential—a critical factor in metastasis. The notion that enhancing CDK5RAP3 functions could serve as a strategic move to control gastric cancer proliferation is particularly intriguing for researchers and oncologists alike.

Despite the provocative implications of the research, the retraction signals a growing trend within the scientific community where preliminary findings need rigorous validation before being embraced. This serves as a reminder that scientific discourse is iterative, and even compelling initial results require validation through repeat studies. The dynamics of cellular signaling, especially in oncogenesis, can be inherently complex. Factors such as tumor microenvironments and genetic variability among patients play pivotal roles in defining a cancer’s behavior, making the replication and cross-validation of results essential.

What makes the implications of CDK5RAP3 particularly salient is the burgeoning interest in signaling pathways as therapeutic targets. The ERK1/2 pathway, for instance, is a well-established player in many malignancies. Researchers have worked to dissect its involvement not just in cell survival but also in metabolic regulation and the maintenance of stemness in tumor cells. The twisted interplay between these signaling networks and tumor suppressors can create a formidable challenge in designing effective interventions.

In light of the retraction, it is imperative for future research to utilize more robust methodologies and transparent reporting standards. Meta-analyses and multi-center trials could enhance the reliability of findings related to CDK5RAP3 and similar tumor suppressors. These approaches will also allow for diverse genetic backgrounds to be studied, increasing the likelihood that findings are relevant across populations.

One concern that arises from retractions is the impact on the scientific community’s trust in published literature. While retractions can seem daunting, they ultimately serve as a vital check against misinformation. The process allows for the refinement of scientific understanding and can pave the way for more accurate conclusions down the line. When researchers approach findings with a critical lens, the end result can be a more solidified body of knowledge.

In gastric cancer research, the multifactorial nature of tumorigenesis necessitates that scholars remain vigilant about validating their findings within broader contexts. While the initial hypothesis surrounding CDK5RAP3 may have offered exciting avenues for potential treatments, it is clear that a more thorough investigation into its biological mechanisms is required. Such diligence will benefit not only the field of oncology but also patients relying on effective cancer therapies.

The balance of innovation and verification is thus a key theme when discussing retracted studies. This meticulousness ensures that when new frontiers in tumor biology are explored, they are done so with scientific rigor and adherence to ethical standards. Moving forward, researchers must aim to strengthen their methodologies and embrace collaborative efforts to ensure the reproducibility of potentially groundbreaking discoveries.

Ultimately, the retraction of the study concerning CDK5RAP3 reflects both the promise and challenges that exist in cancer research. While initial findings may open doors to new treatment possibilities, they must also be interpreted with caution. The ongoing efforts to unravel the complexities of tumor biology will undoubtedly benefit from the lessons learned from past research—emphasizing the importance of validation and reproducibility in advancing the field toward effective cancer treatments.

The journey of scientific inquiry is often fraught with setbacks, yet it is precisely in these moments of reflection and correction that true progress can be made. The discourse surrounding CDK5RAP3 serves as a microcosm of broader challenges faced in oncology and biomedical research—where the need for meticulous validation is paramount in translating laboratory discoveries into real-world applications.

In conclusion, the narrative surrounding the retraction of CDK5RAP3’s significance in gastric cancer opens up a dialogue about the responsibilities researchers have in ensuring the reliability of their work. It underscores the importance of a collective effort to uphold the integrity of scientific inquiry, aiming ultimately toward a future where cancer therapies are as robust as the research that informs them.

The scientific community’s pursuit of accuracy and one that continues to push the boundaries of knowledge in oncology is ongoing. As researchers glean insights from both successes and failures, there lies an inherent hope that such processes will ameliorate the way forward in the battle against cancer.

Ultimately, the journey toward understanding how key molecules like CDK5RAP3 interact within cancer pathways is vital, suggesting that while challenges may be abundant, resilience and dedication to rigorous science will lead to better outcomes for patients afflicted by this devastating disease.

Subject of Research: CDK5RAP3 and its role in human gastric cancer.

Article Title: Retraction Note: CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancer.

Article References:

Lin, Jx., Yoon, C., Li, P. et al. Retraction Note: CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancer.
Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03338-9

Image Credits: AI Generated

DOI:

Keywords: CDK5RAP3, gastric cancer, tumor suppressor, ERK1/2 signaling, cancer research, retraction.

In recent years, research has increasingly targeted the molecular pathways involved in cancer progression and treatment resistance. The DDR1 receptor, a receptor tyrosine kinase, has emerged as a significant player in mediating the cellular responses to the tumor microenvironment. In the context of breast cancer, DDR1 influences not just tumor growth, but also the cancerous cells’ ability to withstand conventional treatments like radiotherapy. The insights provided by this study underscore the complexity of cancer biology and the need for innovative therapeutic strategies to overcome treatment-related challenges.

Radiotherapy, a cornerstone of breast cancer treatment, aims to destroy cancer cells by damaging their DNA. However, not all tumors respond equally to this therapy. Understanding the molecular underpinnings of radioresistance has become a vital area of research. The research led by Wang and colleagues identifies an influential pathway that could hold the key to understanding why some breast cancer tumors resist effective treatment. Specifically, they examine how DDR1 is activated, leading to downstream effects that bolster cancer cell survival in response to radiation.

The intricate connection between DDR1 and the AMPK/SIRT1/PGC-1α pathway is particularly compelling. AMP-activated protein kinase (AMPK) serves as a cellular energy sensor that regulates metabolic processes and influences cell survival. SIRT1, a NAD+-dependent deacetylase, plays a crucial role in cellular stress responses, while PGC-1α is a master regulator of mitochondrial biogenesis and energy metabolism. The interplay between these components forms a protective mechanism that enables breast cancer cells to evade the damaging effects of radiation.

The research findings demonstrate that DDR1 activation leads to increased AMPK activity, which subsequently activates SIRT1. This cascade of enzymatic activities culminates in the promotion of PGC-1α expression, significantly enhancing mitochondrial function. Increased mitochondrial biogenesis and metabolic efficiency provide cancer cells with the energy necessary to withstand radiation-induced damage. Therefore, targeting the DDR1-mediated pathway could represent a novel strategy to enhance the efficacy of breast cancer treatments.

In a broader context, the implications of these findings are significant, not only for breast cancer therapy but also for our understanding of how solid tumors sustain their growth in hostile environments. By elucidating the mechanisms through which DDR1 reinforces radioresistance, researchers can develop more effective therapeutic alternatives. This could involve strategies to inhibit DDR1 or block its downstream signaling pathway, thus rendering cancer cells more susceptible to radiotherapy.

Furthermore, the intricacies of the tumor microenvironment must also be considered. Tumors are not isolated entities; they engage with surrounding tissues, immune cells, and extracellular matrices to develop adaptive mechanisms that support their survival and proliferation. DDR1’s role in mediating these interactions suggests that successful treatment will require a multi-faceted approach, targeting both the tumor and its environment.

As research continues to unravel the complexities of cancer biology, collaborative efforts among various fields such as molecular biology, pharmacology, and clinical oncology will be paramount. Engaging in interdisciplinary research not only accelerates the discovery of effective treatments but also broadens the understanding of cancer as a systemic illness, rather than merely a cluster of rogue cells. The study by Wang and colleagues exemplifies this perspective by integrating various aspects of molecular signaling and therapeutic resistance.

In conclusion, the research into DDR1’s role in breast cancer highlights the pressing need for strategies that go beyond traditional radiotherapy approaches. Understanding the mechanisms that enable tumor cells to resist treatment can pave the way for innovative therapies that not only target the cancer cells themselves but also their supporting microenvironment. As scientists and clinicians work together to bridge the gap between basic and applied research, the hope for more effective breast cancer treatments becomes increasingly tangible.

This evolving discourse on cancer treatment further emphasizes the importance of personalized medicine approaches, where therapeutic strategies are tailored to individual tumor profiles. As our understanding deepens, clinicians may become equipped with the knowledge to predict which patients are likely to benefit from specific treatments based on their tumor’s molecular characteristics. This promise of personalized therapies represents a compelling front in the ongoing battle against breast cancer.

Thus, as the scientific community collectively navigates the intricate landscape of cancer treatment, the findings described by Wang, Chen, and Wei et al., offer both optimism and a call to action. Continued exploration of the DDR1 pathway and its downstream effects is essential for developing comprehensive strategies to combat treatment resistance in breast cancer, ultimately improving survival rates and quality of life for patients fighting this formidable disease.

Subject of Research: Mechanisms of DDR1 in Reinforcing the Resistance to Radiotherapy in Breast Cancer

Article Title: Mechanisms of DDR1 in Reinforcing the Resistance to Radiotherapy in Breast Cancer Through the AMPK/SIRT1/PGC-1α Pathway.

Article References: Wang, S., Chen, Y., Wei, J. et al. Mechanisms of DDR1 in Reinforcing the Resistance to Radiotherapy in Breast Cancer Through the AMPK/SIRT1/PGC-1α Pathway. Biochem Genet (2026). https://doi.org/10.1007/s10528-025-11314-w

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10528-025-11314-w

Keywords: DDR1, breast cancer, radiotherapy resistance, AMPK, SIRT1, PGC-1α, signaling pathways, cancer treatment.

Thyroid cancer, although relatively uncommon compared to other malignancies, is increasing in incidence, particularly among younger women. The need for reliable predictive tools is more pressing than ever, as the prognosis and treatment pathways vary significantly depending on the specific recurrence risks associated with different thyroid cancer types. Traditional methods of assessing risk have relied heavily on histopathological evaluations, which can be subjective and vary between practitioners. TC Check aims to streamline this process through advanced computational techniques.

The foundation of TC Check lies in the implementation of explainable machine learning, an approach designed not only to make predictions but also to clarify the decision-making processes behind them. This transparency is crucial in a clinical setting, where the need for understanding the rationale behind a prediction can influence patient trust and decision-making. By utilizing a dataset that encompasses a variety of clinical variables, the application leverages algorithms that deliver insights not just into likely outcomes but also into the factors that drive these predictions.

Indeed, the emphasis on explainability sets TC Check apart from many existing software tools that often function as a ‘black box.’ In applications of machine learning, where complex algorithms can obscure the logic behind predictions, the researchers opted for methods that allow both clinicians and patients to understand the underlying data correlations and risk factors. This is particularly beneficial in a field where patient-specific decisions significantly impact health trajectories.

The creators of TC Check tested the application using a diverse patient dataset, ensuring that the model remained robust across different demographic and clinical backgrounds. Effectively, this enhances the validity of the tool, as it signifies that clinicians can deploy it among various patient populations while still obtaining accurate predictions of recurrence risk. The adaptability of TC Check could serve as a prototype for other cancers and medical conditions, showcasing the versatility of explainable machine learning applications in medicine.

Furthermore, the engagement with healthcare providers during development has been a crucial aspect of TC Check’s creation. The team actively sought feedback from oncologists regarding the functionalities they deemed most beneficial for patient care. Insights gathered during this phase highlighted important features, including user-friendly interfaces and data visualization tools, which allow for clear communication of predicted risks to patients. This cooperative development process has ensured that the application will have a real-world impact from its inception.

In addition to improving clinical decision-making, TC Check also holds potential for enhancing patient education. By providing patients with clear, interpretable predictions regarding their recurrence risk, the application empowers individuals by offering them a better understanding of their health status. This, in turn, allows patients to engage more meaningfully in discussions about their treatment options and the necessary lifestyle adjustments that might reduce recurrence risk. In an age where patient-centered care is a priority, tools like TC Check are invaluable.

The approach to data handling within TC Check is also commendable. With growing concerns about patient privacy and data security in digital health applications, the developers have taken necessary precautions to ensure that all information is anonymized and stored securely. This adherence to ethical data practices not only fulfills regulatory requirements but also enhances trust in the application and its predicted outcomes among users.

As TC Check continues to be pilot tested in clinical settings, researchers and healthcare providers are keeping a close eye on its performance and the implications of its utilization. Early feedback has been overwhelmingly positive, with clinicians noting improved efficiency in evaluating recurrence risks without compromising the quality of patient care. Additionally, as machine learning technology evolves, there are plans for iterative updates that will allow TC Check to refine its algorithms as new data becomes available.

With thyroid cancer on the rise and the importance of personalized treatment strategies underscored in medical literature, TC Check represents a critical advancement in the fight against this disease. The integration of technology and clinical practice, especially through explainable machine learning, showcases the transformative potential of innovation in healthcare. As more applications like TC Check emerge, we are bound to witness an increasing trend toward data-driven decision-making in oncology.

The implications of tools like TC Check extend beyond individual patient benefits; they also provide valuable insights into broader population health trends. By accumulating and analyzing data from multiple sources, researchers can identify patterns that inform public health initiatives aimed at combating thyroid cancer. This data-driven approach may also lead to future studies that explore the genetic predispositions associated with higher recurrence risks, offering further opportunities for prevention and timely interventions.

In summary, TC Check is more than just an application—it’s a multifaceted tool poised to elevate the standards of care in thyroid cancer management. By prioritizing explainability within machine learning, empowering patients, and ensuring rigorous data practices, it sets a precedent for future innovations in cancer care. The collective effort in developing this application embodies the spirit of collaboration and progress that is essential for advancing healthcare in an increasingly complex world.

As we look forward to the future of oncology, one thing is clear: technological advancements like TC Check will play an integral role in shaping patient outcomes and redefining the landscape of cancer treatment and recurrences. We must continue investing in and leveraging these innovations, ensuring that they are accessible to all, and working tirelessly towards a world where recurrence risk prediction is both accurate and comprehensible.

Subject of Research: Prediction of thyroid cancer recurrence using explainable machine learning.

Article Title: TC check: a web app for thyroid cancer recurrence prediction using explainable machine learning.

Article References:

Wen, H., Li, X. & Zhao, X. TC check: a web app for thyroid cancer recurrence prediction using explainable machine learning. J Cancer Res Clin Oncol 152, 14 (2026). https://doi.org/10.1007/s00432-025-06377-6

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00432-025-06377-6

Keywords: Thyroid cancer, recurrence prediction, explainable machine learning, digital health, patient empowerment, data privacy.

Ferroptosis stands distinct from other forms of cell death, including apoptosis and necrosis. It is triggered by the accumulation of reactive oxygen species (ROS) and is tightly linked to cellular iron metabolism. This unique form of regulated cell death arises primarily from the depletion of glutathione, an essential antioxidant that safeguards cells from oxidative stress. The intricate relationship between iron metabolism and lipid peroxidation underscores the importance of controlling cellular iron levels when seeking to exploit ferroptosis for therapeutic purposes.

Recent studies have highlighted the complex role of ferroptosis in gastric cancer, especially concerning drug resistance. Traditional therapies often fail due to the cancer cells’ ability to adapt and survive through various mechanisms. Understanding how ferroptosis can be induced in these cells presents a promising strategy for overcoming the challenges of conventional therapies. Researchers are now focusing on identifying compounds that can selectively induce ferroptosis in gastric cancer cells, thereby enhancing their susceptibility to existing treatments.

Emerging evidence suggests that specific dietary interventions and pharmacological agents could augment ferroptotic signaling pathways in cancer treatment. For instance, certain polyunsaturated fatty acids have been shown to promote ferroptosis, leading to cancer cell death. Targeting metabolic pathways involved in iron sequestration and antioxidant response may further enhance the efficacy of such approaches, making them suitable adjuncts to traditional chemotherapy.

A key component in the quest to leverage ferroptosis for therapeutic gain is its regulation by various signaling molecules. Molecules such as p53 and nuclear factor erythroid 2-related factor 2 (Nrf2) play critical roles in modulating ferroptotic responses, influencing the cellular fate in the context of cancer development. The crosstalk between these pathways presents an exciting frontier for therapeutic exploration, as manipulating their activities could create a potent environment for ferroptosis.

Moreover, the immune system’s role in the modulation of ferroptosis adds another layer of complexity to this intriguing topic. Studies have shown that the tumor microenvironment significantly influences ferroptotic activity and can dictate the effectiveness of therapies that aim to induce this form of cell death. Identifying how immune cells interact with cancer cells during ferroptotic processes may yield critical insights into the development of combination therapies that incorporate immune checkpoint inhibitors alongside agents promoting ferroptosis.

As ferroptosis gains recognition as a novel target in cancer therapy, the academic community is gearing up to explore its broader implications. There is an increasing focus on unraveling the molecular mechanisms that govern ferroptosis and its interactions with established cancer treatment paradigms. Comprehensive research in this area promises to enhance our understanding of gastric cancer biology and may result in the development of innovative treatment strategies that ultimately improve patient outcomes.

The potential of ferroptosis extends beyond gastric cancer, as it has been implicated in various other malignancies, including breast, colorectal, and prostate cancers. The universal nature of this cell death pathway raises the possibility of a broader therapeutic application across multiple cancer types, offering hope for patients who face limited options. As scientists continue to decode the complexities of ferroptosis, the possibility of discovering synergistic therapies that target multiple pathways simultaneously becomes more attainable.

Communication between researchers, clinicians, and industry will be pivotal in translating the promising findings surrounding ferroptosis into actionable therapies. Collaborative efforts to establish clinical trials focused on ferroptosis modulation are essential to evaluate the safety and efficacy of these innovative approaches in human subjects. Engaging in dialogue across disciplines will catalyze the pace of research and enhance our collective understanding of ferroptosis in the context of cancer.

With each passing day, our understanding of cancer biology grows deeper, and the promise of ferroptosis as a therapeutic modality is beginning to materialize. As researchers continue to unravel the layers of this intricate process, the potential for transforming how we approach gastric cancer therapy remains bright. Fueled by innovation and curiosity, the exploration of ferroptosis stands to revolutionize cancer treatment paradigms in the years to come, moving us closer to the realization of targeted, effective therapies that can fundamentally alter patient experiences in the face of this challenging disease.

Continued investigations will focus not only on the basic science of ferroptosis but also on the translation of these findings into clinical practice. Far-reaching implications for patient management and treatment strategies are on the horizon, as ferrototic agents could offer new hope against resistant cancer forms. As the landscape of cancer research evolves, ferroptosis remains at the forefront of revolutionary therapeutic strategies, exemplifying how a deeper understanding of cell death mechanisms could reshape the future of oncology.

In conclusion, the ongoing research into the mechanisms and applications of ferroptosis represents a significant breakthrough in our understanding of gastric cancer treatment. As scientists unravel its complexities, the hope is that ferroptosis will emerge as a key player in developing effective therapies that counteract drug resistance and improve outcomes for patients battling this challenging disease. With the relentless pursuit of knowledge and clinical advancement, the future of cancer therapy may very well hinge on harnessing the power of ferroptosis.

Subject of Research: Ferroptosis and its role in drug resistance and therapy of gastric cancer.

Article Title: Research progress on ferroptosis in drug resistance and therapy of gastric cancer.

Article References: Liu, Y., Jia, L., Yang, L. et al. Research progress on ferroptosis in drug resistance and therapy of gastric cancer. J Cancer Res Clin Oncol 152, 1 (2026). https://doi.org/10.1007/s00432-025-06372-x

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00432-025-06372-x

Keywords: Ferroptosis, Gastric Cancer, Drug Resistance, Lipid Peroxidation, Cancer Therapy, Iron Metabolism, Antioxidants, Cell Death Pathways, Clinical Trials, Treatment Strategies.

Colorectal cancer is notably heterogeneous at the molecular level, comprising various intrinsic molecular subtypes that differ not only in their biological characteristics but also in their responses to treatment. Traditionally, cancer classification has relied heavily on histopathological evaluation, which, while still crucial, often falls short in capturing the complexity of the disease. The introduction of molecular profiling has heralded a new era in oncology, enabling clinicians and researchers to better understand the genetic landscape of CRC and its implications for therapy.

The team led by Tsantoulis has developed a novel classifier that effectively identifies and categorizes the intrinsic consensus molecular subtypes (CMS) of colorectal cancer. By leveraging advanced machine learning techniques, the classifier analyzes genomic data to discern patterns that were previously undetectable with standard analytical methods. This robust system represents a paradigm shift that could potentially redefine treatment protocols in the field of oncology by facilitating the selection of more effective, individualized therapies based on a patient’s specific cancer subtype.

One of the key challenges in oncology has been the inability to predict which patients will respond favorably to particular therapies. The research team’s classifier addresses this issue head-on by integrating data from multiple cohorts and employing rigorous validation steps to ensure its reliability. This thorough approach not only adds to the credibility of the findings but also amplifies the potential for clinical application, as it equips healthcare providers with tools that can enhance decision-making processes regarding treatment plans.

The announcement of these findings is particularly timely; as cancer treatment is becoming increasingly personalized, understanding the molecular underpinnings of CRC is crucial. The classification of tumors based on their molecular characteristics can lead to the development of targeted therapies that exploit specific vulnerabilities in cancer cells. This targeted approach is pivotal, given that traditional chemotherapy often leads to suboptimal outcomes accompanied by significant side effects, stemming from its indiscriminate action on healthy and cancerous tissues alike.

Moving forward, creating a standardized system that integrates the classifier into clinical practice could drastically change the landscape of CRC treatment. Researchers anticipate that widespread adoption of such classifiers could shorten the time needed to identify the most suitable treatments for patients, allowing for quicker clinical decisions and potentially improving survival rates. Speeding up treatment pathways in this way will not only enhance the quality of life for patients but may also lessen the burden on healthcare systems, which is critical in light of the growing incidence of CRC globally.

Moreover, the implications of these findings extend beyond individual treatment. Understanding the molecular subtypes of CRC can foster advancements in early detection strategies, allowing for the identification of high-risk populations. Early intervention is strongly correlated with improved outcomes in cancer care, making this research significant not just for therapeutic strategies but also for preventative measures.

Furthermore, collaboration between scientists, clinicians, and technology experts will be essential for translating this research into practice. As the classifier undergoes further validation and refinement, its deployment in clinical settings will require careful integration into existing workflows. Training programs for oncologists and medical professionals will play a critical role in ensuring that these advanced tools are utilized to their fullest potential, leading to patient-centric care.

In addition to its clinical applications, this research paves the way for future studies aimed at exploring other cancer types through similar molecular classification systems. The evolution of machine learning and artificial intelligence technologies presents unprecedented opportunities to analyze complex datasets, providing invaluable insights into tumor biology and behavior. As more data becomes accessible, the classifiers developed in this research could evolve, thereby continuously enhancing diagnostic accuracy and treatment outcomes across various cancers.

As this research gains traction within the scientific community, it is expected to stimulate further discourse and investigation into the molecular landscape of not only colorectal cancer but other malignancies as well. The ongoing dialogue between researchers and clinicians will be critical in ensuring that these findings are disseminated and utilized to their optimal effect, impacting patient care on a global scale.

Ultimately, Tsantoulis and colleagues have taken an important step towards a future where cancer treatment is more scientifically informed and personalized. By harnessing the power of high-throughput genomic analysis and machine learning, they have laid down a template that could serve as a model for future research endeavors. As the world of oncology continues to evolve, it is innovations like these that bring hope for improved treatment strategies and better outcomes for patients facing the battle against cancer.

In conclusion, as the research community rallies around these findings, an exciting new chapter in the fight against colorectal cancer unfolds. With the potential to revolutionize patient care through personalized treatment options and improved classification methods, this study stands as a testament to the power of innovation in science. It highlights the remarkable ability of researchers to reshape our understanding of diseases, ultimately leading us closer to a future where cancer is more manageable, and patient lives are improved.

Subject of Research: Colorectal Cancer Molecular Subtypes

Article Title: A robust classifier for the intrinsic consensus molecular subtypes in colorectal cancer

Article References: Tsantoulis, P., Hong, Y., Wirapati, P. et al. A robust classifier for the intrinsic consensus molecular subtypes in colorectal cancer.
J Transl Med (2025). https://doi.org/10.1186/s12967-025-07363-9

Image Credits: AI Generated

DOI:

Keywords: Colorectal Cancer, Molecular Subtypes, Machine Learning, Precision Medicine, Oncology, Genetic Profiling

Scientists at the Tokyo University of Science, led by Associate Professor Satoshi Ueha and Professor Kouji Matsushima, have pioneered a groundbreaking approach that deciphers the complex genetic orchestration underpinning CD8+ T cell expansion within tumors. Their work, published in the prestigious journal Nature Communications on October 20, 2025, delineates a ‘pan-immunotherapy expansion signature’—a specific set of genes whose expression heralds the proliferative surge of these essential immune cells, offering a predictive biomarker that spans diverse immunotherapeutic modalities.

The foundational challenge addressed by Ueha and colleagues stems from the dynamic yet elusive nature of T cell responses inside the tumor milieu. Traditional methods provided static snapshots, insufficient to capture the kinetic changes in clonal expansion over time. To surmount this, the team engineered an innovative ‘multi-site tumor model’ in mice, implanting tumors at distinct anatomical locations. This allowed longitudinal sampling of T cell populations, tracking their clonal fate with unprecedented granularity using the unique sequences of T cell receptors (TCRs) as natural molecular barcodes.

Leveraging next-generation single-cell RNA sequencing combined with TCR sequencing, the researchers could pinpoint hundreds of distinct CD8+ T cell clones and map their proliferative trajectories over the course of a week. This dual sequencing approach unveiled a remarkable finding: expanding T cell clones consistently exhibited a coordinated gene expression program prior to entering proliferation. This ‘expansion signature’ encompasses genes involved in cell cycle regulation, metabolic reprogramming, and effector functions, collectively priming the cells for robust division and anti-tumor activity.

Critically, the expansion signature proved to be a reliable predictor not only in untreated animal models but across varied checkpoint blockade therapies, including PD-L1, CTLA-4, and LAG-3 inhibitors, which are cornerstone treatments in immuno-oncology. The signature’s predictive power also extended to human clinical samples, correlating strongly with improved survival outcomes in patients receiving programmed cell death protein 1 (PD-1) blockade and chimeric antigen receptor (CAR) T cell therapies. Such universality elevates the expansion signature as a transformative biomarker capable of transcending therapy types and patient heterogeneity.

One of the most intriguing dimensions of the study lies in the temporal dynamics of the expansion signature itself. While its expression diminishes as T cells enter contraction phases, a reservoir of T cells harboring latent expansion potential persists within the tumor. This finding was elegantly validated when administration of LAG-3 blockade reactivated the signature and reignited proliferation in previously contracted clones, underscoring the signature’s role not only as a marker of active expansion but also as an indicator of cellular readiness to re-enter the proliferative state under renewed immunotherapeutic pressure.

This opens tantalizing possibilities for clinical intervention. By monitoring the expansion signature longitudinally, oncologists could gain real-time insights into the tumor-immune landscape, identifying early on which patients are mounting effective responses and who may benefit from reinvigoration strategies. Moreover, therapeutic designs could be tailored to modulate this genetic program directly, fine-tuning the proliferative capacity of tumor-infiltrating T cells to maximize anti-tumor efficacy while mitigating risks associated with immune overactivation.

From a mechanistic standpoint, this study sheds light on the gene networks that orchestrate T cell fate decisions within the hostile tumor microenvironment, where suppressive signals and metabolic challenges often impede immune cell function. Understanding how these genetic pathways can be harnessed or rejuvenated could revolutionize immunotherapy, shifting the paradigm from empirical treatment selection to precision-guided immune modulation.

The implications extend beyond oncology. Immune cell dynamics are fundamental to a host of pathological conditions and therapeutic interventions, including infectious diseases and autoimmune disorders. The concept of a functional gene signature predicting immune cell expansion could inspire analogous research in other biological contexts, fostering a new generation of dynamic biomarkers that offer temporal resolution and actionable insights.

Ueha and his team’s approach also underscores the power of integrating cutting-edge technologies—single-cell analysis, TCR sequencing, and innovative in vivo models—to unravel immune complexity at a resolution that was once unimaginable. Their work exemplifies a shift toward quantitative and predictive immunology that could redefine how researchers and clinicians monitor and manipulate immune responses.

As the immune-oncology field increasingly embraces personalized medicine, the discovery of a pan-immunotherapy expansion signature provides a vital tool for patient stratification and therapeutic monitoring. It promises to enhance the precision of immunotherapies by pinpointing when and how to intervene, potentially increasing response rates and improving long-term survival in patients with diverse cancer types.

This advance also offers a framework for next-generation immunodynamic therapies aimed at dynamically tuning T cell proliferation within tumors. By controlling this proliferative burst with fine granularity, treatments could be optimized not only for maximal tumor eradication but also to minimize adverse immune-related side effects, thereby improving the overall safety and efficacy profile of cancer immunotherapy.

Looking ahead, the researchers envision the integration of the expansion signature into clinical workflows as a biomarker for real-time evaluation of immunotherapy efficacy. Combined with adaptive therapeutic strategies, this biomarker could help circumvent resistance mechanisms that limit the durability of current treatments, steering the immune system back into an active, tumor-controlling state whenever it begins to falter.

In sum, this landmark study from Tokyo University of Science represents a paradigm shift in our understanding of intratumoral CD8+ T cell biology. It offers a potent genetic signature that not only predicts and tracks T cell expansion across multiple immunotherapy platforms but also offers the means to therapeutically harness this process. The revelation of this pan-immunotherapy signature marks a critical step toward personalized, dynamic immunotherapy, heralding a new era of precision oncology where treatment is guided by the evolving tempo of the immune response itself.

Subject of Research: Animals

Article Title: A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions

News Publication Date: 20-Oct-2025

References: DOI: 10.1038/s41467-025-64107-5

Image Credits: Dr. Satoshi Ueha from Tokyo University of Science, Japan

Keywords: T lymphocytes, Immune cells, Cancer immunotherapy, Cancer genomics, Blood cells, Leukocytes, Lymphocytes, Immunodynamics, Tumor immunology, Checkpoint blockade therapy

The study, spearheaded by Sarkar and colleagues, delves into the intricate relationship between RNA polymerase I transcription and the proliferation of cancer cells. The essential role of RNA polymerase I in synthesizing the ribosomal RNA components necessary for protein synthesis makes it a critical player in cellular growth and division. In many cancers, the dysregulation of this pathway leads to unchecked cellular growth, making it an attractive target for therapeutic intervention.

In seeking to exploit this vulnerability, researchers synthesized NSH76, a compound that selectively disrupts the interaction between RRN3, a cofactor essential for RNA polymerase I function, and the polymerase itself. This targeted action is pivotal since it minimizes the impact on normal cellular processes, thus reducing potential side effects associated with broader-spectrum chemotherapeutic agents. The design and development of NSH76 involved a comprehensive understanding of the structural biology of the polymerase complex, allowing scientists to pinpoint and inhibit RRN3 with remarkable specificity.

Through a series of in vitro experiments, the efficacy of NSH76 was tested against various cancer cell lines, revealing a pronounced reduction in cellular proliferation. The results were not merely a statistical anomaly; they showcased a clear connection between the inhibition of RNA polymerase I activity and subsequent apoptosis in cancerous cells. This exciting revelation provides a solid foundation for further development and potential clinical applications of the compound.

One key aspect scrutinized was the resistance mechanisms often employed by cancer cells in response to therapeutic challenges. Investigators meticulously dissected how these cells could potentially adapt to the inhibition of RNA polymerase I. By using genomic and proteomic analyses, the team observed that certain oncogenic pathways might compensate for the inhibited transcription, suggesting a need for combination therapies. This adaptive response highlights the importance of holistic treatment approaches that can counter the dynamic nature of cancer biology.

Additionally, the research extended beyond the laboratory, including a series of animal model studies aimed at evaluating the in vivo efficacy and safety profile of NSH76. Early results were encouraging, demonstrating significant tumor regression in treated mice compared to controls. These findings not only bolster confidence in the validity of targeting RNA polymerase I but also emphasize the potential of NSH76 as a contender in the landscape of molecularly targeted therapies.

The implications of such a discovery cannot be overstated, particularly in the context of personalized medicine. As the understanding of an individual patient’s tumor microenvironment becomes increasingly nuanced, the potential for tailoring therapies to target specific molecular vulnerabilities grows. NSH76, with its focused action, embodies the principles of precision oncology, allowing for a therapeutic option that could be finely tuned to the unique characteristics of different tumors.

Moreover, the compound’s synthesis and functional validation pave the way for additional derivatives that could enhance potency or reduce off-target effects further. The advancement of medicinal chemistry in conjunction with technological evolution, such as artificial intelligence and machine learning, promises a new era of drug discovery. This paradigm could yield more advanced inhibitors based on the insights gained from NSH76.

In terms of societal impact, the progression from discovery to clinical application holds enormous potential. As more effective treatments become available, the hope of transforming cancer from a terminal diagnosis into a manageable condition draws closer to reality. The work done by Sarkar et al. exemplifies a beacon of hope, illustrating the capacity for science to innovate and adapt in the face of difficult challenges.

The journey from the lab bench to a cancer clinic is fraught with hurdles, yet promisingly, the research community is urging forward. Next steps will include extensive clinical trials and partnerships with pharmaceutical companies capable of scaling production and ensuring comprehensive testing. As NSH76 inches closer to human application, the anticipation for what lies ahead is palpable.

Through this trailblazing work, Sarkar and the team not only provide insights into the workings of RNA polymerase I but also raise critical questions about how to approach cancer therapy moving forward. The potential for NSH76 to become a cornerstone of future treatment regimens is a testament to the evolutionary nature of scientific inquiry, proving that persistence in research may pave an untrodden path toward cancer eradication.

In conclusion, the introduction of NSH76 represents a dynamic advancement in the therapeutic landscape of oncology. With its specificity and scientifically-rooted promise, the compound illuminates the path towards a more refined and effective treatment strategy, encouraging optimism in the fight against cancer.

Subject of Research: Selective inhibition of RRN3 and RNA polymerase I transcription

Article Title: NSH76: a selective inhibitor of RRN3 and RNA polymerase I transcription with potential for cancer therapy.

Article References:

Sarkar, S.S., Sharma, M., Karmakar, A. et al. NSH76: a selective inhibitor of RRN3 and RNA polymerase I transcription with potential for cancer therapy.
J Transl Med 23, 1131 (2025). https://doi.org/10.1186/s12967-025-06588-y

Image Credits: AI Generated

DOI:

Keywords: RNA polymerase I, cancer therapy, selective inhibitor, NSH76, RRN3, transcription, precision oncology.

Hepatocellular carcinoma, one of the most prevalent forms of liver cancer, poses significant treatment challenges, primarily due to its late-stage diagnosis and the complexity of its tumor microenvironment. The role of metabolic alterations in cancer progression has become a focal point in understanding tumor biology. This study meticulously examined the metabolic landscape of HCC to uncover the connections between lysine metabolism and immune responses. By integrating various omics technologies, including genomics, proteomics, and metabolomics, the team aimed to provide a comprehensive view of the biochemical changes associated with HCC.

Lysine, an essential amino acid, plays a crucial role in various cellular processes, including protein synthesis, enzyme activity, and cellular signaling. The downregulation of tumor lysine metabolism observed in HCC has far-reaching implications, suggesting that the cancer cells may be adapting their metabolic programs to survive in a challenging microenvironment. This metabolic shift not only supports tumor growth but also interferes with the functionality of immune cells, creating an immunosuppressive landscape conducive to tumor progression.

The research team utilized advanced analytical methods to characterize the metabolic alterations in HCC tissues compared to healthy liver tissues. Through mass spectrometry and RNA sequencing, they identified significant changes in the expression levels of genes involved in lysine metabolism. Their findings indicated a marked reduction in key enzymes responsible for lysine catabolism, which can lead to an accumulation of metabolites that influence immune response pathways. The researchers hypothesize that this metabolic adaptation allows HCC to evade immune surveillance and enhances its resilience against therapeutic interventions.

Moreover, the study highlighted the interplay between tumor lysine metabolism and specific immune cell populations within the tumor microenvironment. The infiltration of immune cells, such as T cells and macrophages, was closely monitored, revealing that altered lysine metabolism correlates with a diminished presence of cytotoxic T cells. This observation suggests that the metabolic state of tumor cells directly affects the recruitment and activity of immune cells, ultimately shaping the efficacy of immunotherapies. Furthermore, the downregulation of lysine metabolism appears to impact the secretion of inflammatory cytokines, further promoting an immunosuppressive milieu.

These findings are particularly relevant given the rising interest in immunotherapies for HCC treatment. Understanding how metabolic dysregulation affects immune responses could pave the way for innovative therapeutic strategies. The integration of lysine metabolism modulation alongside existing immune checkpoint inhibitors holds promise for enhancing treatment responses in HCC patients. This dual approach may not only reverse the immunosuppressive effects of tumor metabolism but also improve the overall survival rates of patients.

Additionally, the research emphasizes the importance of personalized medicine in the treatment of HCC. Identifying patients with distinct metabolic profiles can guide the selection of appropriate therapies, potentially leading to more effective outcomes. The study encourages further investigations into the metabolic pathways involved in HCC and their relationship with immune cell dynamics.

As the field of cancer research continues to evolve, the implications of lysine metabolism extend beyond HCC. This study sets a precedent for exploring the metabolic underpinnings of various cancers and their influence on immune modulation. The potential to manipulate metabolic pathways as a therapeutic adjunct could revolutionize cancer treatment paradigms in the coming years.

In conclusion, Lu et al.’s study provides crucial insights into the metabolic intricacies of hepatocellular carcinoma, shedding light on how downregulated tumor lysine metabolism reshapes the immune microenvironment. By employing a multi-omics profiling strategy, the research underscores the interconnectedness of metabolism and immunity, urging further exploration into metabolic interventions as a means to bolster therapeutic responses. Such advancements not only enhance our understanding of cancer biology but also open new avenues for innovative and effective treatments against one of the most challenging malignancies faced by patients today.

Subject of Research: Metabolism and immune microenvironment in hepatocellular carcinoma.

Article Title: Multi-omics profiling reveals downregulated tumor lysine metabolism reshaping the immune microenvironment and therapeutic responses in hepatocellular carcinoma.

Article References: Lu, X., Qiang, M., Li, R. et al. Multi-omics profiling reveals downregulated tumor lysine metabolism reshaping the immune microenvironment and therapeutic responses in hepatocellular carcinoma. J Transl Med 23, 1117 (2025). https://doi.org/10.1186/s12967-025-07056-3

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07056-3

Keywords: Hepatocellular carcinoma, lysine metabolism, immune microenvironment, cancer research, multi-omics profiling.

Lung adenocarcinoma, a subtype of non-small cell lung cancer, has seen increasing incidence rates globally and poses substantial treatment challenges due to its propensity to metastasize. The complexity of tumor biology and the molecular intricacies associated with the metastatic process render it essential to unravel the underlying mechanisms of these transformations. The study under discussion presents compelling evidence that KLF5, a member of the Krüppel-like factor family of transcription factors, plays a pivotal role in facilitating this process.

At the heart of KLF5’s mechanism is its involvement in regulating EMT, a biological process where epithelial cells acquire mesenchymal properties, leading to enhanced migratory and invasive capabilities. The dysregulation of EMT is recognized as a vital step in cancer progression, and the findings of this study underscore KLF5’s critical function as a transcriptional regulator that influences the expression of genes associated with this transition. Through extensive experimentation, the researchers established that KLF5 expression correlates with increased EMT markers in lung adenocarcinoma cells.

The novel interaction between KLF5 and RHPN2 is particularly intriguing, given RHPN2’s relatively less understood role in cancer biology. RHPN2, or Rhophilin 2, is known to be involved in regulating cellular signaling pathways that impact cellular morphology and migration. This study elucidates how KLF5 indirectly modulates EMT by influencing the expression of RHPN2, thereby creating a regulatory axis that could be vital for enhancing the invasive potential of lung adenocarcinoma cells.

Through a series of detailed experiments, including in vitro cell migration assays and in vivo metastasis models, the researchers demonstrated that silencing KLF5 led to decreased expression of RHPN2 and subsequently reduced cellular migratory capabilities. Conversely, overexpression of KLF5 amplified RHPN2 levels, resulting in increased invasiveness. These findings establish a functional link between KLF5 and RHPN2 in promoting the metastatic phenotype in lung adenocarcinoma, emphasizing the potential for targeting this axis in clinical settings.

Additionally, the study also investigates the downstream signaling pathways affected by KLF5 overexpression and RHPN2 activity. The researchers evaluated key pathways such as the Wnt, Notch, and TGF-β signaling pathways, all of which have well-established roles in regulating EMT and cancer progression. Their findings revealed that KLF5’s influence on RHPN2 expression is mediated, in part, by these pathways, creating a complex interplay that further dictates the metastatic behavior of lung cancer cells.

As the study delves deeper into the implications of the KLF5-RHPN2 axis, it raises poignant questions about potential therapeutic avenues. Targeting KLF5 directly may pose challenges due to its multifunctional nature, but strategies aimed at modulating RHPN2 expression or its downstream signaling effects could prove beneficial. The development of small-molecule inhibitors or monoclonal antibodies targeting RHPN2 presents an exciting frontier for lung cancer treatment, especially for patients with metastatic disease.

Moreover, the study’s findings initiate a broader dialogue regarding the personalization of cancer therapies. Understanding the specific molecular drivers behind a patient’s cancer can significantly impact therapeutic decisions. As clinicians begin to integrate such molecular insights into treatment algorithms, individual variability in KLF5 and RHPN2 expression may guide more effective and targeted interventions.

Addressing the clinical relevance of these discoveries, this research holds promise for improving outcomes in lung adenocarcinoma patients. By identifying KLF5 and RHPN2 as key players in the metastatic cascade, oncologists may be better equipped to design combination therapies that effectively halt the spread of cancer. Furthermore, these insights may also facilitate the development of predictive biomarkers, allowing for the stratification of patients based on their risk of metastasis.

The implications of this study extend beyond lung cancer; a better understanding of KLF5 and RHPN2 may provide insights into other cancer types characterized by aggressive metastatic behavior. As ongoing research strives to unravel the complex molecular landscape of cancer, findings such as these will be invaluable in guiding future investigations.

In summary, the work by Zhang, Wang, and Yang presents a significant stride in cancer research, elucidating the role of KLF5 in the advancing metastatic cascade of lung adenocarcinoma through its interaction with RHPN2. As the scientific community continues to dissect the nuances of cancer biology, this study serves as a crucial reminder of the potential for innovative therapeutic strategies rooted in molecular understanding.

The findings underscore the importance of continuous research in cancer-related biology to address the growing burden of metastatic disease. Through collaborative efforts among scientists, clinicians, and pharmaceutical companies, the tools needed to combat cancer’s most aggressive manifestations are steadily being developed, offering hope for patients worldwide.

As we look to the future, the interplay between transcription factors like KLF5 and cellular signaling pathways will undoubtedly remain a focal point in cancer research. The journey of translating scientific discoveries into clinical realities is fraught with challenges, but with each study, including this one, we inch closer to effective interventions that can significantly alter the course of lung adenocarcinoma and potentially other malignant diseases.

Subject of Research: Lung adenocarcinoma metastasis, role of KLF5 and RHPN2 in epithelial-mesenchymal transition.

Article Title: KLF5 facilitates lung adenocarcinoma metastasis by regulating the epithelial-mesenchymal transition pathway through RHPN2.

Article References:

Zhang, T., Wang, Rq., Yang, Yb. et al. KLF5 facilitates lung adenocarcinoma metastasis by regulating the epithelial-mesenchymal transition pathway through RHPN2.
J Transl Med 23, 1078 (2025). https://doi.org/10.1186/s12967-025-07150-6

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07150-6

Keywords: KLF5, RHPN2, lung adenocarcinoma, epithelial-mesenchymal transition, metastasis, cancer research.